Cell Line Development

Reducing timelines in generating clonal cell lines for therapeutic protein production

Introduction

In order to produce high yields of recombinant proteins for therapeutic applications, stable producer cell lines need to be developed. Mammalian host cell lines, such as CHO or HEK 293, are typically the system of choice because of the importance of consistent post-translational modifications. 

web-Cytena_f_sight_side_final_freigestellt

Proof of clonality

Clear and traceable evidence of single-cell deposition

SINGLE-CELL CLONING AND PROOF OF CLONALITY

Following transfection, single cells need to be isolated from transfected pools. Traditionally, this crucial step has been performed by limiting dilution. Based on early regulatory guidelines released by the U.S. Food and Drug Administration (FDA) and others, the production cell line of recombinant products is to be cloned from a single progenitor cell in order to minimize population heterogeneity and facilitate isolation and subsequent selection of high producing clones.  

Our solution

To ensure that cell lines are clonally derived, multiple rounds of limiting dilutions are required, a time- and labor-intensive process. Our single-cell printer™ dispensing technology allows for deterministic single-cell isolation, offers documented image-based proof of clonality, and provides efficient and fast single-cell seeding combined with excellent cell viability and zero risk of cross-contamination.

Early suspension culture

After single-cell cloning, cells are typically cultured under static conditions for several weeks before well-growing clones are transferred to shaken deep well or 24-well plates. After additional cultivation, selected clones are then transferred to larger volumes and finally to shake flasks or mini bioreactors. Hence, during the first weeks after cloning, cells are cultured under static conditions, which do not match the culture environment the cells experience in later stages of the process and during production. Our innovative microbioreactor platform, the c.bird™, was developed to enable suspension culture early in the cell line development process.

Related publication

Related products

web-Cytena_c_sight_front_final_freigestellt

c.sight™

Isolate single cells in 96- & 384-well plates Bright field nozzle imaging with 10x magnification. Cell line development and single-cell genomics.

web-Cytena_f_sight_front_final_freigestellt

f.sight™

Isolate green fluorescent eukaryotic cells in well plates. Bright field and fluorescence imaging. Fully tunable to enable even low intensity samples.

Join our webinars to learn more